Routine Neutral

2026-11-06 16:06

- Mankind Pharma Limited has informed the stock exchange about the schedule of upcoming meetings with investors or analysts. - The filing provides routine compliance details regarding the schedule of investor interactions.

Business Update Neutral

2026-11-06 16:05

Concall Schedule Concall Date: From November 16, 2026 to November 19, 2026 Concall Time: Not Specified

Business Update Neutral

2026-11-05 13:47

- Mankind Pharma Limited has been assigned an Environmental, Social, and Governance (ESG) rating of 64.8 for FY26 by SES ESG Research Private Limited. - The rating was independently assigned based on publicly available information without any engagement from the company.

Business Update Positive

2026-11-05 13:27

- Mankind Pharma received an independent ESG rating of 64.8 for FY26 from SES ESG Research Private Limited. - The rating was assigned based on publicly available information without direct company engagement.

Business Update Neutral

2026-11-03 17:47

Concall Schedule Concall Date: November 5, 2026 Concall Time: Not specified

Business Update Neutral

2026-11-03 17:41

- Mankind Pharma Limited announced participation in an Investor Conference hosted by Ashika Stock Services Limited on November 5, 2026, in Mumbai. - The meeting type will be One-on-One or Group Meeting. - No unpublished price sensitive information (UPSI) will be discussed during the interaction.

Financials Positive

2026-10-30 15:22

Q2 FY27 Consolidated Revenue ₹4,338Cr vs ₹3,697Cr (▲17.3% YoY) EBITDA ₹1,175Cr vs ₹924Cr (▲27.2% YoY) PAT ₹716Cr vs ₹520Cr (▲37.7% YoY) EBITDA Margin 27.1% vs 25% (▲210bps)

Business Update Positive

2026-10-30 15:21

Current scenario - Q2 FY27 revenue from operations grew 17.3% YoY to ₹4,338 Cr vs ₹3,697 Cr. - EBITDA for the quarter increased by 27.2% YoY to ₹1,175 Cr with an EBITDA margin of 27.1% (expansion of 210 bps YoY). - Profit After Tax (PAT) for Q2 FY27 grew 37.7% YoY to ₹716 Cr, with PAT margin improving to 16.5%. - Domestic business revenue grew 14.8% YoY to ₹3,657 Cr, outperforming IPM with secondary sales growth of 15.7%. - International business revenue grew 33% YoY to ₹680 Cr, driven by strong performance in Mankind International and BSV's branded specialty. Changes in trends - Chronic portfolio share expanded by 80 bps YoY to 37.4%, led by strong outperformance in cardio, anti-diabetes, and chronic respiratory therapies. - Consumer healthcare business grew moderately at ₹229 Cr, impacted by softer category offtake and regional weakness, though e-commerce channel surged 55%. Management Guidance & Outlook - Full-year R&D spend is guided at the upper end of 2.8% to 3% of revenue, accounting for the impact of ACTx. - Capex as a percentage of revenue is maintained at 6% to 7% for FY27. - Net debt reduced to ₹2,639 Cr with net debt to adjusted EBITDA at 0.6x, remaining on track to repay acquisition-related debt by FY28.

Financials Neutral

2026-10-29 20:39

- CRISIL has reaffirmed the credit rating of CRISIL AA+/Stable for Non-Convertible Debentures worth ₹400 crore and ₹2,100 crore. - CRISIL has withdrawn the credit rating for Non-Convertible Debentures worth ₹2,500 crore and Commercial Paper worth ₹1,500 crore upon company request.

Business Update Neutral

2026-10-29 20:29

- CRISIL has reaffirmed the credit rating of CRISIL AA+/Stable for Non-Convertible Debentures amounting to ₹400 crore and ₹2,100 crore. - CRISIL has withdrawn the credit rating for Non-Convertible Debentures of ₹2,500 crore and Commercial Paper of ₹1,500 crore.

Business Update Positive

2026-10-27 17:19

Investor presentation outlining Mankind Pharma's business evolution, operational scale, R&D capabilities, and strategic growth pillars. Key highlights include achieving ₹14,278 Cr revenue in FY26, expanding chronic segment share towards ~50% by FY30E, scaling in-house manufacturing to ~75%, and driving new product launches in specialty and chronic segments.

Business Update Positive

2026-10-27 17:15

Mankind Pharma released its investor presentation for October 2026 highlighting long-term revenue growth, market leadership, R&D capabilities, manufacturing expansion, and strategic pillars for future outperformance against the Indian Pharmaceutical Market (IPM). - FY26 revenue reached ₹14,278 Cr with an 18.1% CAGR over FY21–26, driven by chronic portfolio expansion, BSV acquisition, and in-licensing deals. - Outlined an eight-pillar growth strategy targeting ~50% chronic share by FY30E, scaling hospital business, and advancing innovative bets like NCEs and biologics.

Business Update Neutral

2026-10-26 19:55

- Mankind Pharma Ltd has submitted the audio recording link for the Earnings Conference Call held on October 26, 2026, regarding Q2 & H1 FY27 financial results. - The filing is made in compliance with Regulations 30 and 51 of the SEBI (LODR) Regulations, 2015.

Routine Neutral

2026-10-26 19:45

- Mankind Pharma Limited has submitted the audio recording link for the Earnings Conference Call held on October 26, 2026, regarding Q2 & H1 FY27 financial results. - The submission complies with Regulations 30 and 51 of the SEBI (LODR) Regulations, 2015.

Business Update Positive

2026-10-26 16:35

- Q2 FY27 Revenue grew 17.3% YoY to ₹4,338 Cr. - EBITDA rose 27.2% YoY to ₹1,175 Cr with margins expanding 210 bps to 27.1%. - PAT surged 37.7% YoY to ₹716 Cr. - Net debt reduced to ₹2,639 Cr; announced acquisition of Armed Cell Therapeutics.

Financials Positive

2026-10-26 15:31

Q2 FY27 Consolidated Revenue ₹4,338 Cr vs ₹3,697 Cr (▲17.3% YoY) EBITDA ₹1,175 Cr vs ₹924 Cr (▲27.2% YoY) PAT ₹716 Cr vs ₹520 Cr (▲37.7% YoY) EBITDA Margin 27.1% vs 25.0% (▲210bps)

Financials Positive

2026-10-26 15:30

Q2 FY27 Consolidated Revenue ₹4,338Cr vs ₹3,697Cr (▲17.3% YoY) EBITDA ₹1,175Cr vs ₹924Cr (▲27.2% YoY) PAT ₹716Cr vs ₹520Cr (▲37.7% YoY) EBITDA Margin 27.1% vs 25.0% (▲210bps)

Business Update Positive

2026-10-26 15:30

- Q2 FY27 Revenue from Operations increased 17.3% YoY to ₹4,338 Cr. - EBITDA grew 27.2% YoY to ₹1,175 Cr with margin expanding 210 bps to 27.1%. - Profit After Tax jumped 37.7% YoY to ₹716 Cr. - Exports rose 32.7% YoY; Domestic business grew 14.8% YoY. - Entered CAR-T therapies via Armed Cell Therapeutics acquisition.

Financials Neutral

2026-10-26 15:27

Q2 FY27 Standalone Revenue ₹3,145.22 Cr vs ₹2,636.95 Cr (▲19.3% YoY) EBITDA ₹932.69 Cr vs ₹703.90 Cr (▲32.5% YoY) PAT ₹581.95 Cr vs ₹459.80 Cr (▲26.6% YoY) EBITDA Margin 29.7% vs 26.7% (▲296bps) - Board approved Scheme of Amalgamation of wholly owned subsidiaries Prolijune Lifesciences and Pavi Buildwell into Mankind Pharma.

Financials Positive

2026-10-26 15:24

Q2 FY27 Consolidated Revenue ₹4,338Cr vs ₹3,697Cr (▲17.3% YoY) EBITDA ₹1,175Cr vs ₹924Cr (▲27.2% YoY) PAT ₹716Cr vs ₹520Cr (▲37.7% YoY) EBITDA Margin 27.1% vs 25.0% (▲210bps)

Financials Neutral

2026-10-26 15:23

Q2 FY27 Standalone Revenue ₹3,145.22Cr vs ₹2,636.95Cr (▲19.3% YoY) EBITDA ₹932.69Cr vs ₹703.90Cr (▲32.5% YoY) PAT ₹581.95Cr vs ₹459.80Cr (▲26.6% YoY) EBITDA Margin 29.7% vs 26.7% (▲296bps) - Board approved Scheme of Arrangement for amalgamation of wholly owned subsidiaries Prolijune Lifesciences and Pavi Buildwell into Mankind Pharma Limited.

Financials Neutral

2026-10-26 15:20

Q2 FY27 Standalone Revenue ₹3,145.22Cr vs ₹2,636.95Cr (▲19.3% YoY) EBITDA ₹932.69Cr vs ₹703.90Cr (▲32.5% YoY) PAT ₹581.95Cr vs ₹459.80Cr (▲26.6% YoY) EBITDA Margin 29.7% vs 26.7% (▲300bps)

Financials Neutral

2026-10-26 15:18

Q2 FY27 Standalone Revenue ₹3,145.22Cr vs ₹2,636.95Cr (▲19% YoY) EBITDA ₹932.69Cr vs ₹703.90Cr (▲33% YoY) PAT ₹581.95Cr vs ₹459.80Cr (▲27% YoY) EBITDA Margin 29.7% vs 26.7% (▲296bps) Board approved Scheme of Amalgamation of wholly-owned subsidiaries Prolijune Lifesciences and Pavi Buildwell into Mankind Pharma.

Financials Positive

2026-10-26 15:18

Q2 FY27 Standalone Revenue ₹3,145Cr vs ₹2,637Cr (▲19% YoY) EBITDA ₹933Cr vs ₹704Cr (▲33% YoY) PAT ₹582Cr vs ₹460Cr (▲27% YoY) EBITDA Margin 30% vs 27% (▲300bps) - Board approved scheme of amalgamation of wholly-owned subsidiaries Prolijune Lifesciences and Pavi Buildwell into Mankind Pharma. - Noted scheme of amalgamation of step-down subsidiary Upakarma Ayurveda into Mankind Consumer Products.

Financials Neutral

2026-10-26 15:17

Q2 FY27 Standalone Revenue ₹3,145Cr vs ₹2,637Cr (▲19% YoY) EBITDA ₹933Cr vs ₹704Cr (▲33% YoY) PAT ₹582Cr vs ₹460Cr (▲27% YoY) EBITDA Margin 30% vs 27% (▲296bps) Board approved Scheme of Amalgamation of wholly-owned subsidiaries Prolijune Lifesciences and Pavi Buildwell with the Company.

Financials Positive

2026-10-26 15:13

Q2 FY27 Standalone Revenue ₹3,145.22Cr vs ₹2,636.95Cr (▲19.3% YoY) EBITDA ₹932.69Cr vs ₹703.90Cr (▲32.5% YoY) PAT ₹581.95Cr vs ₹459.80Cr (▲26.6% YoY) EBITDA Margin 29.65% vs 26.69% (▲296bps)

Financials Positive

2026-10-26 15:09

Q2 FY27 Consolidated Revenue ₹4,338Cr vs ₹3,697Cr (▲17% YoY) EBITDA ₹1,175Cr vs ₹924Cr (▲27% YoY) PAT ₹716Cr vs ₹520Cr (▲38% YoY) EBITDA Margin 27.1% vs 25.0% (▲211bps)

Business Update Neutral

2026-10-22 18:55

Concall Schedule Concall Date: October 26, 2026 Concall Time: 05:00 P.M. (IST)

Business Update Neutral

2026-10-22 18:53

Concall Schedule Concall Date: October 26, 2026 Concall Time: 05:00 P.M. (IST)

Business Update Neutral

2026-10-22 16:01

Concall Schedule Concall Date: October 27, 2026 Concall Time: In-person (Group) in Mumbai

Business Update Neutral

2026-10-22 15:59

Concall Schedule Concall Date: October 27, 2026 Concall Time: In-person (Group) in Mumbai

Business Update Neutral

2026-10-22 15:46

Concall Schedule Concall Date: October 26, 2026 Concall Time: 05:00 P.M. (IST) (Rescheduled from 06:00 P.M.)

Business Update Neutral

2026-10-22 15:41

Concall Schedule Concall Date: October 26, 2026 Concall Time: 05:00 P.M. (IST)

Routine Positive

2026-10-16 17:04

- Mankind Pharma Ltd has successfully paid the interest and full redemption amount for its Non-Convertible Debentures (NCDs) on October 16, 2026. - Total interest paid for ISIN INE634S07025 was ₹50.07 crore gross and for ISIN INE634S07033 was ₹99.90 crore gross. - Full redemption amount of ₹1,250 crore was paid for ISIN INE634S07025 on its maturity date.

Business Update Positive

2026-10-15 20:46

- Mankind Pharma has been assigned an ESG Rating of '71' for FY26 by NSE Sustainability Ratings and Analytics Limited. - The rating was independently assigned based on publicly available information without company engagement.

Business Update Positive

2026-10-15 20:39

- Mankind Pharma has been assigned an ESG rating of '71' for FY26 by NSE Sustainability Ratings and Analytics Limited. - The rating was independently assigned based on publicly available information without prior engagement by the company.

Business Update Positive

2026-10-15 19:37

Mankind Pharma board approved an additional investment of up to EUR 45Mn in its wholly-owned subsidiary, Mankind Pharma (Netherlands) B.V., taking the total investment limit to EUR 50Mn. - The subsidiary will acquire a 70% majority stake in Armed Cell Therapeutics B.V. (ACTx), a Belgium-based biotechnology company, for an investment of EUR 48Mn. - ACTx focuses on next-generation chimeric antigen receptor T-cell (CAR-T) therapies for cancer, with lead programs targeting non-Hodgkin lymphoma and small cell lung cancer. - This strategic acquisition marks Mankind Pharma's entry into next-generation CAR-T therapies to build a global innovation-led pharmaceutical business.

Business Update Positive

2026-10-15 19:36

- Mankind Pharma approved an additional investment of up to EUR 45Mn in its wholly-owned subsidiary, Mankind Pharma (Netherlands) B.V., increasing the aggregate investment limit to EUR 50Mn. - The funds will be utilized to acquire a 70% majority stake in Armed Cell Therapeutics B.V. (ACTx) for EUR 48Mn through the subsidiary. - ACTx is a Belgium-incorporated biotechnology company developing next-generation CAR-T cell therapies for cancer, with lead programs targeting non-Hodgkin lymphoma and small cell lung cancer. - This strategic acquisition marks Mankind Pharma's entry into next-generation CAR-T therapies to build a global innovation-led pharmaceutical business.

Business Update Positive

2026-10-15 19:31

Mankind Pharma has approved an additional investment of up to EUR 45 million in its subsidiary Mankind Pharma (Netherlands) B.V., bringing the total investment limit to EUR 50 million. - The funds will be utilized to acquire a 70% majority stake in Armed Cell Therapeutics B.V. (ACTx) for EUR 48 million in installments. - ACTx is a Belgium-incorporated biotechnology company developing next-generation CAR-T cell therapies for cancer, with lead programs targeting non-Hodgkin lymphoma and small cell lung cancer. - This acquisition marks Mankind Pharma's strategic entry into next-generation CAR-T therapies as part of its long-term goal to build a global innovation-led pharmaceutical business.

Business Update Positive

2026-10-15 19:30

Mankind Pharma board approved an additional investment of up to EUR 45 million in Mankind Pharma (Netherlands) B.V., increasing the aggregate limit to EUR 50 million. - The subsidiary will acquire a 70% majority stake in Armed Cell Therapeutics B.V. (ACTx), a Belgium-incorporated biotechnology company, for EUR 48 million. - ACTx focuses on next-generation CAR-T cell therapies for cancer, with lead programs in non-Hodgkin lymphoma and small cell lung cancer.

Business Update Positive

2026-10-15 19:30

Mankind Pharma's board approved an additional investment of up to EUR 45Mn in its wholly-owned subsidiary, Mankind Pharma (Netherlands) B.V., increasing the aggregate limit to EUR 50Mn. - The subsidiary will invest EUR 48Mn to acquire a 70% majority stake in Armed Cell Therapeutics B.V. (ACTx), a Belgium-based biotechnology company. - ACTx develops next-generation CAR-T therapies for cancer, with lead programs targeting non-Hodgkin lymphoma and small cell lung cancer.

Business Update Positive

2026-10-15 19:26

Mankind Pharma approved an additional investment of up to EUR 45Mn in its wholly-owned subsidiary, Mankind Pharma (Netherlands) B.V., increasing the aggregate investment limit to EUR 50Mn. - The subsidiary will utilize EUR 48Mn to acquire a 70% majority stake in Armed Cell Therapeutics B.V. (ACTx), a Belgium-incorporated biotechnology company. - ACTx specializes in next-generation CAR-T cell therapies for cancer, with lead programs targeting non-Hodgkin lymphoma and small cell lung cancer. - This strategic acquisition marks Mankind Pharma's entry into global innovation-led pharmaceutical businesses and next-generation CAR-T therapies.

Business Update Neutral

2026-10-12 11:47

Concall Schedule Concall Date: October 26, 2026 Concall Time: 06:00 P.M. (IST)

Business Update Neutral

2026-10-12 11:46

Concall Schedule Concall Date: October 26, 2026 Concall Time: 06:00 P.M. (IST)

Governance Neutral

2026-10-08 17:21

- Board meeting scheduled on Monday, October 26, 2026. - To consider and approve unaudited standalone and consolidated financial results for Q2 and H1 ended September 30, 2026. - Trading window remains closed until October 28, 2026.

Governance Neutral

2026-09-28 15:55

- S.R. Batliboi & Co. LLP resigned as the Statutory Auditors of Bharat Serums and Vaccines Limited (BSV), a material wholly owned subsidiary of Mankind Pharma Limited, with effect from September 28, 2026. - The resignation is due to the initiation of voluntary liquidation proceedings of BSV under Section 59 of the Insolvency and Bankruptcy Code, 2016. - Under the voluntary liquidation regulations, the liquidator is prohibited from engaging any professional who has served as the auditor of the company during the preceding five years.

Governance Neutral

2026-09-28 15:51

- S.R. Batliboi & Co. LLP resigned as the Statutory Auditors of Bharat Serums and Vaccines Limited (BSV), a material wholly owned subsidiary of Mankind Pharma Limited, effective September 28, 2026. - The resignation is a consequence of the initiation of voluntary liquidation proceedings for BSV under Section 59 of the Insolvency and Bankruptcy Code, 2016. - Under the voluntary liquidation regulations, a liquidator is prohibited from engaging any professional who has served as the auditor of the company in the preceding five years. - The auditors confirmed there are no other material reasons for their resignation.

Routine Neutral

2026-09-25 13:44

- Trading window for dealing in securities of the Company will be closed effective October 01, 2026. - Closure will continue until 48 hours after the declaration of financial results for the quarter and half-year ending September 30, 2026. - Board meeting date will be intimated in due course.

Routine Neutral

2026-09-25 13:20

- Trading window closure effective from October 01, 2026. - Closure remains until 48 hours post declaration of Q2/H1 FY27 financial results (ended September 30, 2026). - Board meeting date to consider results will be intimated in due course.

Governance Neutral

2026-09-17 19:18

- Mankind Pharma Limited announced the voting results for the appointment of Mr. Anish Vanraj Bafna (DIN: 02925792) as a Non-Executive Independent Director for a term of five years commencing August 10, 2026. - The special resolution was passed with requisite majority through remote e-voting, with 99.96% of votes cast in favour.

Governance Positive

2026-09-17 19:15

- Mankind Pharma Limited announced that the special resolution for the appointment of Mr. Anish Vanraj Bafna as a Non-Executive Independent Director for five years was passed with 99.9627% votes in favour through remote e-voting (August 19 to September 17, 2026).

Governance Neutral

2026-09-17 19:10

- Mankind Pharma Limited announced the voting results for the Postal Ballot and Scrutinizer's Report on September 17, 2026. - The Special Resolution for the appointment of Mr. Anish Vanraj Bafna as a Non-Executive Independent Director for a term of five years was passed with a requisite majority of 99.96% votes in favor.

Business Update Positive

2026-09-15 19:56

- Mankind Pharma received an ESG rating of 68.21 from Niche99 ESG Ratings. - The rating places the company in the "Leader" category for FY 2025-26. - Niche99 independently prepared the report without the Company's engagement.

Business Update Positive

2026-09-15 19:52

- Mankind Pharma received an independent 'Leader' ESG rating of 68.21 from Niche99 ESG Ratings for FY 2025-26. - The rating is based on public disclosures, and the company did not engage Niche99 for the report.

Business Update Neutral

2026-09-11 14:51

- Investor Conferences Schedule - 17th Sep'26: Jefferies 5th India Forum (Gurgaon) - 18th Sep'26: Health care Forum (Mumbai) - 21st Sep'26: J.P. Morgan India Conference (Mumbai)

Routine Neutral

2026-09-11 14:43

New Filing detected. See link for details.

Business Update Neutral

2026-09-07 17:14

- Members of Mankind Pharma's wholly-owned subsidiary, Bharat Serums and Vaccines Limited (BSVL), approved its voluntary liquidation on September 7, 2026. - The liquidation is subject to approval from BSVL's creditors.

Business Update Neutral

2026-09-07 17:12

- Mankind Pharma's wholly-owned subsidiary, Bharat Serums and Vaccines Limited (BSVL), received approval from its members on September 7, 2026, for voluntary liquidation. - This liquidation is subject to approval from BSVL's creditors.

Ownership Neutral

2026-09-01 18:05

- Mankind Pharma Limited allotted 49,112 equity shares of ₹1/- face value under its Employee Stock Option Plan 2022 on September 1, 2026. - The paid-up share capital increased from 41,29,95,978 to 41,30,45,090 Equity Shares. - The exercise price was ₹860.00/- per equity share.

Ownership Neutral

2026-09-01 18:00

- Mankind Pharma Limited allotted 49,112 equity shares on September 1, 2026, to eligible employees under its ESOP Plan 2022. The shares have a face value of ₹1 each and an exercise price of ₹860.00. - This allotment increased the paid-up share capital from 41,29,95,978 to 41,30,45,090 equity shares.

Business Update Neutral

2026-08-31 20:09

- Mankind Pharma Limited completed the sale of its 100% stake in Broadway Hospitality Services Private Limited on August 31, 2026. - Broadway ceased to be a wholly-owned subsidiary from the effective date.

Business Update Neutral

2026-08-31 20:08

- Mankind Pharma Limited completed the transfer of its 100% stake in Broadway Hospitality Services Private Limited on August 31, 2026. - Broadway has ceased to be a wholly-owned subsidiary of the Company.

Governance Negative

2026-08-30 22:29

CRITICAL RED FLAG DETECTED

- Mr. Bharat Anand completed his second term as an Independent Director of Mankind Pharma Limited. His tenure ceased effective August 30, 2026. - He also ceased to be a member of the Audit, Nomination and Remuneration, Risk Management, and Corporate Social Responsibility Committees.

Governance Negative

2026-08-30 22:27

CRITICAL RED FLAG DETECTED

- Mr. Bharat Anand ceased to be an Independent Director of Mankind Pharma Limited due to the completion of his second term, effective August 30, 2026. - He has also ceased to be a member of the Audit, Nomination and Remuneration, Risk Management, and Corporate Social Responsibility Committees.

Business Update Positive

2026-08-26 16:46

- Mankind Pharma's Board on August 26, 2026, approved the voluntary liquidation of its 96% direct subsidiary, Bharat Serums and Vaccines Limited (BSVL). - The business of BSVL will be consolidated with Mankind Pharma on a going concern basis to drive operational efficiency and improved management.

Business Update Positive

2026-08-26 16:44

- Board approved the voluntary liquidation of Bharat Serums and Vaccines Limited (BSVL), a material wholly-owned subsidiary (96% direct, 4% indirect). - BSVL's business will be consolidated with Mankind Pharma on a going concern basis. - The move aims to drive operational efficiency, consolidate business, improve cash management, and rationalize expenses.

Business Update Positive

2026-08-26 16:41

- Board Meeting on Aug 26, 2026, approved voluntary liquidation of 96% held subsidiary Bharat Serums and Vaccines Limited (BSVL). - BSVL's business will be integrated into Mankind Pharma for operational efficiency, business consolidation, and improved cash management.

Business Update Positive

2026-08-26 16:40

- Board approved the initiation of voluntary liquidation process for Bharat Serums and Vaccines Limited (BSVL), a material wholly-owned subsidiary. - BSVL's business will be consolidated with Mankind Pharma on a going concern basis. - This strategic move aims to drive operational efficiency, effective resource utilization, improved organizational execution, cash management, and enhanced governance. - Appian Properties Private Limited, holding 4% of BSVL, will receive cash proportionate to its shareholding.

Business Update Positive

2026-08-22 14:03

- Mankind Pharma's ESG Rating improved to 64 (Strong category) from 57 (Adequate category) by CRISIL ESG Ratings. - The Company's Core ESG Rating also improved to 71 from the previous rating of 60.

Business Update Positive

2026-08-22 14:00

- Mankind Pharma's ESG Rating improved to 64, categorized as "Strong," from the previous rating of 57 ("Adequate"). - The Company's Core ESG Rating also improved to 71 from 60. - The rating was independently assigned by CRISIL ESG Ratings & Analytics Limited based on FY2026 disclosures.

Business Update Positive

2026-08-20 13:39

- Mankind Pharma Limited entered an exclusive in-licensing and marketing agreement with Chongqing Chenan Biopharmaceutical Co., Ltd., China. - The agreement is for the commercialisation of Insulin Degludec and Insulin Degludec + Aspart Combination in India. - This partnership strengthens Mankind Pharma's presence in the diabetes segment and expands its injectable diabetes portfolio.

Business Update Positive

2026-08-20 13:37

- Mankind Pharma entered an exclusive in-licensing and marketing agreement with Chongqing Chenan Biopharmaceutical Co., Ltd., China, on August 20, 2026. - The agreement is for commercialization of Insulin Degludec and Insulin Degludec + Aspart Combination in India. - This strengthens Mankind's presence in the diabetes segment and expands its injectable portfolio.

Governance Positive

2026-08-18 15:53

- Mankind Pharma Limited announces a postal ballot for the appointment of Mr. Anish Vanraj Bafna as a Non-Executive Independent Director for a term of five consecutive years. - E-voting period: August 19, 2026 (9:00 AM IST) to September 17, 2026 (5:00 PM IST). - Results will be declared on or before September 21, 2026. - Mr. Bafna brings over 30 years of experience in the healthcare and medical devices sector.

Governance Neutral

2026-08-18 15:50

- Mankind Pharma Limited issued a Postal Ballot Notice for the appointment of Mr. Anish Vanraj Bafna as a Non-Executive Independent Director for five consecutive years from August 10, 2026. - The e-voting period is from August 19, 2026 (9:00 AM IST) to September 17, 2026 (5:00 PM IST). - Results will be declared on or before September 21, 2026.

Ownership Positive

2026-08-17 23:11

- Mankind Pharma completed realignment of security cover for Non-Convertible Debentures (NCDs). - This resulted in the release of the pledge on 28,280 equity shares (38.68%) of Bharat Serums and Vaccines Limited (BSVL). - No shares of BSVL are now pledged for NCDs. - The revised security cover over tangible/intangible assets is 1.26 times the outstanding NCDs.

Ownership Positive

2026-08-17 23:08

- Mankind Pharma Limited has completed the realignment of the security cover for its Non-Convertible Debentures (NCDs). - As a result, 28,280 pledged equity shares of Bharat Serums and Vaccines Limited (BSVL), constituting 38.68% of BSVL's paid-up equity capital, have been released. - The revised security cover for the NCDs is now 1.26 times the outstanding amount, with no BSVL shares remaining under pledge.

Business Update Positive

2026-08-13 21:32

- Mankind Pharma Limited incorporated its wholly-owned subsidiary, "Mankind Pharma (Netherlands) B.V.", in the Netherlands on August 13, 2026.

Business Update Positive

2026-08-13 21:31

- Mankind Pharma Limited announced the incorporation of its wholly-owned subsidiary, "Mankind Pharma (Netherlands) B.V.", in the Netherlands on August 13, 2026.

Governance Neutral

2026-08-10 16:25

- Board of Directors meeting held on August 10, 2026. - Approved the appointment of Mr. Anish Vanraj Bafna as a Non-Executive Independent Director, effective August 10, 2026. - His appointment is for a term of 5 consecutive years, subject to members' approval via postal ballot.

Governance Positive

2026-08-10 16:23

- The Board of Directors approved the appointment of Mr. Anish Vanraj Bafna as an Additional Director, designated as a Non-Executive Independent Director, effective August 10, 2026. This appointment is for a term of 5 (five) consecutive years, subject to the approval of the members via a Postal Ballot. Mr. Bafna has over 30 years of experience in the healthcare and medical devices sector.

Governance Positive

2026-08-10 16:18

- The Board of Directors approved the appointment of Mr. Anish Vanraj Bafna as an Additional Director, designated as a Non-Executive Independent Director. - The appointment is effective from August 10, 2026, for a term of 5 consecutive years, subject to members' approval via Postal Ballot. - Mr. Bafna has over 30 years of experience in the healthcare and medical devices sector.

Governance Positive

2026-08-10 16:15

- Board approved the appointment of Mr. Anish Vanraj Bafna as an Additional Non-Executive Independent Director for 5 years, effective August 10, 2026, subject to shareholder approval. Mr. Bafna has over 30 years experience in healthcare.

Governance Positive

2026-08-10 16:12

- Mankind Pharma Limited appointed Mr. Anish Vanraj Bafna as an Additional Director, designated as a Non-Executive Independent Director, effective August 10, 2026. This appointment is for a term of 5 consecutive years, subject to shareholder approval via Postal Ballot. Mr. Bafna brings over 30 years of experience in the healthcare and medical devices sector.

Business Update Neutral

2026-08-10 12:44

- Mankind Pharma Limited will participate in investor conferences. - August 13, 2026: Emkay Confluence and Equirus Annual India Conference '26 in Mumbai. - August 17, 2026: Motilal Oswal 22nd Annual Global Investor Conference, 2026 in Mumbai. - No Unpublished Price Sensitive Information (UPSI) will be disclosed.

Business Update Neutral

2026-08-10 12:40

- Investor Conference Schedule - August 13, 2026: Emkay Confluence (Mumbai) - One-on-One / Group Meeting - August 13, 2026: Equirus Annual India Conference '26 (Mumbai) - One-on-One / Group Meeting - August 17, 2026: Motilal Oswal 22nd Annual Global Investor Conference, 2026 (Mumbai) - One-on-One / Group Meeting - No unpublished price sensitive information will be disclosed during these meetings.

Governance Positive

2026-08-06 16:01

- Mankind Pharma Limited's 35th AGM held on August 4, 2026. - All four resolutions, including adoption of financial statements, re-appointment of directors Mr. Rajeev Juneja and Mr. Satish Kumar Sharma, and ratification of cost auditors' remuneration for FY 2026-27, were approved with requisite majority.

Governance Neutral

2026-08-04 17:38

- Mankind Pharma Limited's 35th Annual General Meeting (AGM) was held on August 4, 2026, via video conferencing. - Key items included adopting FY2025-26 financial statements (standalone and consolidated), re-appointing directors, and ratifying cost auditor remuneration. - Auditors' reports had no qualifications or observations.

Governance Neutral

2026-08-04 17:35

- The 35th Annual General Meeting (AGM) of Mankind Pharma Limited was held on August 4, 2026, through video conferencing, concluding at 4:56 P.M. (IST). - Key agenda items included adopting the financial statements for FY 2025-26 and re-appointing Directors and cost auditors.

Business Update Positive

2026-08-04 13:26

- Maintained FY27 double-digit growth guidance for overall business, with Chronic business expected to perform better and Acute business to recover. - Maintained FY27 EBITDA margin guidance of 25.5% to 26.5%. - Gross margin guidance upward of 71% for FY27, taking a conservative approach due to potential commodity price increases and West Asia crisis impacts. - On track to repay acquisition-related debt by FY28, with net debt to adjusted EBITDA ratio at 0.9x in Q1 FY27. - Aims to increase chronic portfolio share to 50% in the medium term from the current 40%. - Consumer Healthcare business expected to achieve high single-digit to double-digit growth from Q2 FY27 onwards. - BSV business expected to deliver high double-digit growth (high teens) for FY27.

Business Update Positive

2026-08-04 13:16

- Consolidated Revenue ₹4,031Cr (▲13% YoY) - EBITDA ₹1,060Cr (EBITDA Margin 26.3%, ▲250bps YoY) - PAT ₹574Cr (▲29.1% YoY, PAT Margin 14.2%, ▲170bps YoY) - Gross margins increased to 72.8% (▲230bps YoY) - Domestic business revenue grew ▲10.5% YoY, driven by Chronic portfolio growth (▲15.8% YoY) and Acute portfolio recovery (▲10.9% YoY). - International business revenue grew ▲29% YoY. - Net debt reduced to ₹3,377Cr; on track to repay acquisition-related debt by FY28. - Maintained FY27 EBITDA guidance of 25.5% to 26.5% and gross margins upward of 71%. - Expects double-digit growth for the full year FY27, confident of progressively outperforming IPM. - Launched new division 'Vistar' and partnered for AI-led drug discovery; attrition has significantly dropped and is under control.

Routine Neutral

2026-07-30 20:33

New Filing detected. See link for details.

Routine Neutral

2026-07-30 20:32

New Filing detected. See link for details.

Financials Neutral

2026-07-30 16:03

CRITICAL RED FLAG DETECTED

- Standalone Revenue ₹2,964.05 Cr vs ₹2,569.73 Cr (▲15.34% YoY) - Standalone EBITDA ₹928.58 Cr vs ₹684.93 Cr (▲35.57% YoY) - Standalone PAT ₹558.49 Cr vs ₹415.27 Cr (▲34.49% YoY) - Standalone EBITDA Margin 31.39% vs 26.65% (▲474 bps) - Company noted pending income tax proceedings for adjustments aggregating to ~₹1,869 Cr, against which appeals have been filed.

Financials Negative

2026-07-30 16:01

CRITICAL RED FLAG DETECTED

- Standalone Revenue ₹2,964.05Cr vs ₹2,569.73Cr (▲15.34% YoY) - EBITDA ₹928.58Cr vs ₹684.93Cr (▲35.57% YoY) - PAT ₹558.49Cr vs ₹415.27Cr (▲34.49% YoY) - EBITDA Margin 31.32% vs 26.65% (▲467bps)

Financials Positive

2026-07-30 15:55

- Consolidated Revenue ₹4,031 Cr vs ₹3,570 Cr (▲12.9% YoY) - EBITDA ₹1,060 Cr vs ₹850 Cr (▲24.7% YoY) - PAT ₹574 Cr vs ₹445 Cr (▲29.1% YoY) - EBITDA Margin 26.3% vs 23.8% (▲250bps)

Financials Positive

2026-07-30 15:55

- Consolidated Revenue ₹4,031Cr vs ₹3,570Cr (▲12.9% YoY) - EBITDA ₹1,060Cr vs ₹850Cr (▲24.7% YoY) - PAT ₹574Cr vs ₹445Cr (▲29.1% YoY) - EBITDA Margin 26.3% vs 23.8% (▲250bps)

Financials Positive

2026-07-30 15:42

CRITICAL RED FLAG DETECTED

- Standalone Revenue ₹2,964.05 Cr vs ₹2,569.73 Cr (▲15.34% YoY) - Standalone EBITDA ₹928.58 Cr vs ₹684.93 Cr (▲35.57% YoY) - Standalone PAT ₹558.49 Cr vs ₹415.27 Cr (▲34.49% YoY) - Standalone EBITDA Margin 31.39% vs 26.65% (▲474bps) - Board approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. - Approved issuance of a corporate guarantee in favour of Bharat Serums and Vaccines Limited (BSV), a wholly owned subsidiary. - Noted ongoing income tax proceedings initiated against the company for which appeals are pending; management believes its position is tenable. - Disclosed the acquisition of the Branded Generic Business of BSV (Women's Health Portfolio) for ₹797 Cr, effective November 1, 2025, resulting in restatement of prior year figures. - Approved the divestment of 100% stake in Broadway Hospitality Services Private Limited for ₹49 Cr and the incorporation of a new subsidiary in Netherlands for R&D.

Financials Positive

2026-07-30 15:34

CRITICAL RED FLAG DETECTED

- Unaudited Standalone Financial Results for Q1 FY27 (quarter ended June 30, 2026) were approved. Consolidated results table is not provided in this filing. - Standalone Operating Revenue ₹2,964.05 Cr vs ₹2,569.73 Cr (▲15.34% YoY) - Standalone EBITDA ₹928.58 Cr vs ₹684.93 Cr (▲35.57% YoY) - Standalone PAT ₹558.49 Cr vs ₹415.27 Cr (▲34.49% YoY) - Standalone EBITDA Margin 31.33% vs 26.65% (▲468bps) - The company's comparative unaudited standalone financial results for Q1 FY26 have been restated due to the acquisition of Bharat Serums and Vaccines Limited (BSV) for ₹797 crores. - Board approved issuance of a corporate guarantee in favour of Bharat Serums and Vaccines Limited (BSV), a wholly owned subsidiary. - The company divested 100% stake in Broadway Hospitality Services Private Limited for ₹49 crores. - **Red Flag**: Income tax proceedings initiated by the Income Tax Department from an earlier search are pending appeal, raising uncertainty.

Financials Neutral

2026-07-30 15:31

CRITICAL RED FLAG DETECTED

- Consolidated Revenue ₹4,030.59 Cr vs ₹3,570.35 Cr (▲13% YoY) - EBITDA ₹1,105.13 Cr vs ₹929.82 Cr (▲19% YoY) - PAT ₹574.09 Cr vs ₹444.62 Cr (▲29% YoY) - EBITDA Margin 27.4% vs 26.0% (▲138bps) - Board approved a corporate guarantee of ₹150 Cr for its wholly-owned subsidiary, Bharat Serums and Vaccines Limited (BSV). - The Company divested its 100% stake in Broadway Hospitality Services Private Limited for ₹49 Cr. - Auditors highlighted ongoing income tax proceedings from FY23-24 with assessment orders making adjustments of ₹1,908.66 Cr, currently under appeal. - Exceptional items include an impairment loss of ₹13.44 Cr related to a greenfield project in Hyderabad.

Financials Positive

2026-07-30 15:24

CRITICAL RED FLAG DETECTED

- Standalone Revenue ₹2,964.05 Cr vs ₹2,569.73 Cr (▲15.3% YoY) - Standalone EBITDA ₹928.58 Cr vs ₹684.93 Cr (▲35.6% YoY) - Standalone PAT ₹558.49 Cr vs ₹415.27 Cr (▲34.5% YoY) - Standalone EBITDA Margin 31.4% vs 26.7% (▲470bps)

MANKIND

Mankind Pharma Limited

Price Chart

Filing History

Unlock Full History